Alison C Roxby

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. pmc Short communication: T cell activation in HIV-1/herpes simplex virus-2-coinfected Kenyan women receiving valacyclovir
    Alison C Roxby
    Department of Medicine, University of Washington, Seattle, WA 98104, USA
    AIDS Res Hum Retroviruses 29:94-8. 2013
  2. pmc Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2
    Alison C Roxby
    Department of Medicine, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 7:e38622. 2012
  3. pmc Herpes simplex virus type 2, genital ulcers and HIV-1 disease progression in postpartum women
    Alison C Roxby
    Department of Medicine, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 6:e19947. 2011
  4. pmc Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial
    Alison L Drake
    Department of Global Health, University of Washington, Seattle 98195 7236, USA
    J Infect Dis 205:366-75. 2012
  5. pmc Infant safety during and after maternal valacyclovir therapy in conjunction with antiretroviral HIV-1 prophylaxis in a randomized clinical trial
    Alison L Drake
    Department of Global Health, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 7:e34635. 2012
  6. pmc Maternal valacyclovir and infant cytomegalovirus acquisition: a randomized controlled trial among HIV-infected women
    Alison C Roxby
    Department of Medicine, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 9:e87855. 2014
  7. pmc Depot Medroxyprogesterone Acetate Use Is Associated With Elevated Innate Immune Effector Molecules in Cervicovaginal Secretions of HIV-1-Uninfected Women
    Brandon L Guthrie
    Departments of Global Health Epidemiology, University of Washington, Seattle, WA Department of Medicine, Solna, Unit of Infectious Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden Department of Medicine, University of Washington, Seattle, WA and Center for Public Health Research, Kenya Medical Research Institute, Nairobi, Kenya
    J Acquir Immune Defic Syndr 69:1-10. 2015

Collaborators

Detail Information

Publications7

  1. pmc Short communication: T cell activation in HIV-1/herpes simplex virus-2-coinfected Kenyan women receiving valacyclovir
    Alison C Roxby
    Department of Medicine, University of Washington, Seattle, WA 98104, USA
    AIDS Res Hum Retroviruses 29:94-8. 2013
    ..Further study is needed to understand the mechanism of HIV-1 RNA reduction following herpes suppression among those coinfected with HIV-1 and HSV-2...
  2. pmc Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2
    Alison C Roxby
    Department of Medicine, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 7:e38622. 2012
    ..Herpes simplex virus type 2 (HSV-2) suppression has been shown to reduce HIV-1 disease progression in non-pregnant women and men, but effects on pregnant and postpartum women have not been described...
  3. pmc Herpes simplex virus type 2, genital ulcers and HIV-1 disease progression in postpartum women
    Alison C Roxby
    Department of Medicine, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 6:e19947. 2011
    ..The impact of HSV-2 on clinical outcomes among HIV-1 infected pregnant women is unclear...
  4. pmc Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial
    Alison L Drake
    Department of Global Health, University of Washington, Seattle 98195 7236, USA
    J Infect Dis 205:366-75. 2012
    ..The effect of herpes simplex virus type 2 (HSV-2) suppression on human immunodeficiency virus type 1 (HIV-1) RNA in the context of prevention of mother-to-child transmission (PMTCT) interventions is unknown...
  5. pmc Infant safety during and after maternal valacyclovir therapy in conjunction with antiretroviral HIV-1 prophylaxis in a randomized clinical trial
    Alison L Drake
    Department of Global Health, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 7:e34635. 2012
    ..However, the safety profile of prolonged infant and maternal exposure to acyclovir in the context of antiretrovirals (ARVs) for prevention of mother-to-child HIV-1 transmission (PMTCT) has not been described...
  6. pmc Maternal valacyclovir and infant cytomegalovirus acquisition: a randomized controlled trial among HIV-infected women
    Alison C Roxby
    Department of Medicine, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 9:e87855. 2014
    ..Studies in HIV-1-infected infants and HIV-1-exposed, uninfected infants link early cytomegalovirus (CMV) acquisition with growth delay and cognitive impairment. We investigated maternal valacyclovir to delay infant acquisition of CMV...
  7. pmc Depot Medroxyprogesterone Acetate Use Is Associated With Elevated Innate Immune Effector Molecules in Cervicovaginal Secretions of HIV-1-Uninfected Women
    Brandon L Guthrie
    Departments of Global Health Epidemiology, University of Washington, Seattle, WA Department of Medicine, Solna, Unit of Infectious Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden Department of Medicine, University of Washington, Seattle, WA and Center for Public Health Research, Kenya Medical Research Institute, Nairobi, Kenya
    J Acquir Immune Defic Syndr 69:1-10. 2015
    ..We assessed the local concentration in the female genital mucosa of cationic polypeptides with reported antiviral activity in relation to DMPA use...